cefuroxime axetil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 566 64544-07-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefuroxime axetil
  • cefazine
  • altacef
  • ceftin
  • cefurax
  • oraxim
  • Molecular weight: 510.47
  • Formula: C20H22N4O10S
  • CLOGP: 0.90
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 2
  • TPSA: 189.06
  • ALOGS: -3.54
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 67.90 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.036 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 12.853 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 15.346 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 13.335 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 36.630 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 44.330 % Moderate 0.78
herg hERG pIC50 4.216 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 50.119 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 199.067 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 21.050 % Moderate 0.78
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 16.672 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 14.028 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 271.644 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 37.650 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 35.400 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 42.800 % Moderate 0.78
rat-kpuu-brain Rat brain Kpuu 0.041 % High 1
rh-clint Rat hepatocyte intrinsic clearance 199.067 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.250 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 27 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 567.545 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1987 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 163.19 19.49 33 7461 1017 90619936
Sputum purulent 149.20 19.49 32 7462 1320 90619633
Angioedema 136.52 19.49 78 7416 64798 90556155
Dysphonia 135.85 19.49 77 7417 63007 90557946
Swollen tongue 135.12 19.49 69 7425 45887 90575066
Secondary immunodeficiency 134.78 19.49 32 7462 2094 90618859
Swelling face 122.68 19.49 79 7415 81273 90539680
Anaphylactic reaction 115.02 19.49 78 7416 87446 90533507
Drug hypersensitivity 112.31 19.49 163 7331 463446 90157507
Oesophageal spasm 106.12 19.49 29 7465 3332 90617621
Oesophageal pain 102.97 19.49 30 7464 4344 90616609
Trimethylaminuria 87.80 19.49 15 7479 177 90620776
Full blood count abnormal 85.07 19.49 47 7447 36550 90584403
Drug ineffective for unapproved indication 84.21 19.49 58 7436 66586 90554367
Anaphylactic shock 82.95 19.49 44 7450 31573 90589380
Hypersensitivity 81.04 19.49 139 7355 454538 90166415
Lymphoedema 75.99 19.49 32 7462 13721 90607232
Obstructive airways disorder 70.69 19.49 37 7457 25832 90595121
Pseudomembranous colitis 54.89 19.49 18 7476 3850 90617103
Megacolon 51.29 19.49 15 7479 2199 90618754
Drug intolerance 48.29 19.49 111 7383 447480 90173473
Sleep apnoea syndrome 43.33 19.49 29 7465 31718 90589235
Serous retinal detachment 42.57 19.49 10 7484 624 90620329
Tinnitus 41.85 19.49 32 7462 43070 90577883
Dysbiosis 41.50 19.49 12 7482 1690 90619263
Urticaria 41.05 19.49 84 7410 312650 90308303
Agitation 40.73 19.49 38 7456 67060 90553893
Clostridium difficile infection 37.61 19.49 28 7466 36217 90584736
Abdominal pain 34.00 19.49 90 7404 395631 90225322
Bronchitis 32.87 19.49 51 7443 152876 90468077
Hallucination 31.91 19.49 33 7461 65926 90555027
Myalgia 31.66 19.49 54 7440 175071 90445882
Cystitis 31.59 19.49 33 7461 66685 90554268
Cross sensitivity reaction 31.49 19.49 11 7483 2846 90618107
Joint swelling 30.83 19.49 3 7491 503297 90117656
Breath odour 29.98 19.49 9 7485 1442 90619511
Macular oedema 29.05 19.49 12 7482 4897 90616056
Rash 28.84 19.49 136 7358 795964 89824989
Clostridium difficile colitis 28.53 19.49 21 7473 26685 90594268
Pruritus 27.81 19.49 103 7391 541422 90079531
Intestinal perforation 27.32 19.49 16 7478 13865 90607088
Fluid retention 27.27 19.49 35 7459 88056 90532897
Retinoschisis 27.17 19.49 4 7490 16 90620937
Inhibitory drug interaction 26.71 19.49 10 7484 3153 90617800
Macular detachment 26.65 19.49 5 7489 103 90620850
Oral discomfort 25.83 19.49 14 7480 10469 90610484
Product preparation issue 25.73 19.49 9 7485 2337 90618616
Anterior chamber inflammation 24.95 19.49 6 7488 414 90620539
Oesophagitis haemorrhagic 24.15 19.49 6 7488 474 90620479
Hyperhidrosis 23.28 19.49 41 7453 136264 90484689
White blood cells urine positive 22.75 19.49 11 7483 6487 90614466
Peritonitis 22.19 19.49 16 7478 19689 90601264
Abdominal distension 21.93 19.49 39 7455 130562 90490391
Dermatitis allergic 21.67 19.49 15 7479 17312 90603641
Bacterial test positive 21.30 19.49 10 7484 5529 90615424
Kounis syndrome 21.29 19.49 8 7486 2545 90618408
Alopecia 19.95 19.49 8 7486 495063 90125890
Granulocytopenia 19.86 19.49 10 7484 6431 90614522
Headache 19.58 19.49 130 7364 862616 89758337
Myocardial infarction 19.56 19.49 33 7461 105939 90515014

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vasculitis 215.30 22.36 63 5202 6203 42609867
Neuritis 193.87 22.36 58 5207 6162 42609908
Eosinophilic granulomatosis with polyangiitis 175.12 22.36 58 5207 8580 42607490
Neurological symptom 166.84 22.36 58 5207 9933 42606137
Conjunctivitis allergic 166.53 22.36 51 5214 5860 42610210
Respiratory symptom 164.61 22.36 59 5206 11047 42605023
Capillaritis 164.59 22.36 41 5224 2187 42613883
Pulmonary alveolar haemorrhage 158.58 22.36 62 5203 14754 42601316
Sleep disorder due to a general medical condition 148.75 22.36 62 5203 17391 42598679
Mite allergy 148.38 22.36 45 5220 5001 42611069
Spirometry abnormal 147.51 22.36 45 5220 5101 42610969
Dust allergy 145.94 22.36 45 5220 5287 42610783
Mycotic allergy 145.46 22.36 44 5221 4847 42611223
Antineutrophil cytoplasmic antibody positive 141.63 22.36 42 5223 4323 42611747
Total lung capacity abnormal 136.56 22.36 41 5224 4402 42611668
Normochromic normocytic anaemia 133.89 22.36 48 5217 8983 42607087
Vasculitis 132.47 22.36 58 5207 18336 42597734
Pulmonary fibrosis 126.52 22.36 63 5202 26618 42589452
Obstructive airways disorder 124.95 22.36 61 5204 24698 42591372
Forced expiratory volume decreased 118.57 22.36 42 5223 7588 42608482
Nodule 111.74 22.36 46 5219 12488 42603582
Hypothyroidism 107.30 22.36 60 5205 32024 42584046
Arteriosclerosis coronary artery 103.25 22.36 49 5216 18628 42597442
Full blood count abnormal 100.25 22.36 56 5209 29820 42586250
Arteriosclerosis 95.79 22.36 46 5219 17943 42598127
Wheezing 93.72 22.36 67 5198 54714 42561356
Lung disorder 92.21 22.36 63 5202 47860 42568210
Haemoptysis 89.56 22.36 61 5204 46106 42569964
Asthma 86.01 22.36 67 5198 62247 42553823
Therapeutic product effect incomplete 82.50 22.36 69 5196 70870 42545200
Loss of personal independence in daily activities 80.79 22.36 59 5206 49757 42566313
Productive cough 70.16 22.36 55 5210 51512 42564558
Macular detachment 60.85 22.36 11 5254 119 42615951
Hypoxia 59.51 22.36 57 5208 69729 42546341
Product preparation issue 56.06 22.36 15 5250 1060 42615010
Thrombosis 51.05 22.36 52 5213 68459 42547611
Retinal toxicity 50.68 22.36 12 5253 515 42615555
Kounis syndrome 46.52 22.36 17 5248 3351 42612719
Pulmonary embolism 40.47 22.36 61 5204 119551 42496519
Pain in extremity 38.97 22.36 68 5197 150536 42465534
Anaphylactic reaction 38.48 22.36 36 5229 42707 42573363
Condition aggravated 38.17 22.36 93 5172 260661 42355409
Anterior chamber inflammation 37.81 22.36 9 5256 395 42615675
Anxiety 36.65 22.36 58 5207 118502 42497568
Retinoschisis 32.59 22.36 5 5260 17 42616053
Macular oedema 31.45 22.36 13 5252 3556 42612514
Spinal muscular atrophy 27.46 22.36 7 5258 409 42615661
Serous retinal detachment 25.95 22.36 8 5257 936 42615134
Metabolic disorder 24.73 22.36 12 5253 4776 42611294
Drug reaction with eosinophilia and systemic symptoms 24.40 22.36 28 5237 42047 42574023
Dyspnoea 22.58 22.36 111 5154 442510 42173560

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vasculitis 225.12 19.16 64 11877 6496 110570862
Obstructive airways disorder 196.30 19.16 97 11844 46052 110531306
Neuritis 195.76 19.16 59 11882 7340 110570018
Full blood count abnormal 175.73 19.16 96 11845 55956 110521402
Eosinophilic granulomatosis with polyangiitis 174.43 19.16 59 11882 10627 110566731
Conjunctivitis allergic 173.65 19.16 53 11888 6878 110570480
Capillaritis 166.29 19.16 41 11900 2398 110574960
Respiratory symptom 158.71 19.16 60 11881 14885 110562473
Spirometry abnormal 154.79 19.16 46 11895 5451 110571907
Neurological symptom 152.60 19.16 59 11882 15549 110561809
Mite allergy 152.33 19.16 46 11895 5757 110571601
Pulmonary alveolar haemorrhage 151.38 19.16 63 11878 20087 110557271
Dust allergy 150.81 19.16 46 11895 5955 110571403
Antineutrophil cytoplasmic antibody positive 149.59 19.16 44 11897 5032 110572326
Mycotic allergy 146.91 19.16 45 11896 5909 110571449
Total lung capacity abnormal 145.10 19.16 42 11899 4541 110572817
Anaphylactic reaction 141.18 19.16 109 11832 114191 110463167
Nicotine dependence 141.17 19.16 32 11909 1299 110576059
Sputum purulent 134.94 19.16 33 11908 1865 110575493
Normochromic normocytic anaemia 126.37 19.16 49 11892 13008 110564350
Oesophageal spasm 109.00 19.16 32 11909 3634 110573724
Vasculitis 108.42 19.16 60 11881 35813 110541545
Forced expiratory volume decreased 105.07 19.16 43 11898 13133 110564225
Angioedema 104.63 19.16 86 11855 98414 110478944
Oesophageal pain 102.51 19.16 33 11908 5092 110572266
Arteriosclerosis coronary artery 101.45 19.16 51 11890 25067 110552291
Swollen tongue 100.49 19.16 69 11872 60293 110517065
Dysphonia 97.19 19.16 74 11867 75855 110501503
Secondary immunodeficiency 97.18 19.16 31 11910 4645 110572713
Arteriosclerosis 90.48 19.16 47 11894 24720 110552638
Sleep disorder due to a general medical condition 90.14 19.16 61 11880 52051 110525307
Trimethylaminuria 88.60 19.16 16 11925 199 110577159
Swelling face 88.53 19.16 76 11865 92245 110485113
Hypothyroidism 84.50 19.16 67 11874 72832 110504526
Haemoptysis 81.46 19.16 65 11876 71289 110506069
Macular detachment 79.48 19.16 15 11926 241 110577117
Nodule 78.37 19.16 47 11894 32584 110544774
Therapeutic product effect incomplete 75.17 19.16 106 11835 223699 110353659
Anaphylactic shock 72.10 19.16 53 11888 51493 110525865
Asthma 70.32 19.16 109 11832 250182 110327176
Serous retinal detachment 69.66 19.16 19 11922 1653 110575705
Kounis syndrome 67.30 19.16 25 11916 5900 110571458
Lymphoedema 65.28 19.16 32 11909 14897 110562461
Wheezing 64.61 19.16 106 11835 255124 110322234
Macular oedema 63.37 19.16 25 11916 6941 110570417
Anterior chamber inflammation 62.93 19.16 15 11926 760 110576598
Pulmonary fibrosis 61.51 19.16 65 11876 101977 110475381
Drug ineffective for unapproved indication 61.09 19.16 65 11876 102773 110474585
Retinal toxicity 60.59 19.16 17 11924 1642 110575716
Hypersensitivity 60.35 19.16 134 11807 403864 110173494
Retinoschisis 56.14 19.16 9 11932 51 110577307
Pseudomembranous colitis 54.87 19.16 22 11919 6369 110570989
Productive cough 53.79 19.16 64 11877 114241 110463117
Product preparation issue 51.94 19.16 17 11924 2762 110574596
Drug hypersensitivity 48.05 19.16 132 11809 453958 110123400
Anxiety 45.48 19.16 109 11832 344969 110232389
Thrombosis 44.92 19.16 57 11884 108605 110468753
Hypoxia 44.41 19.16 62 11879 129453 110447905
Megacolon 41.09 19.16 16 11925 4289 110573069
Dysbiosis 39.68 19.16 13 11928 2119 110575239
Retinal infarction 38.77 19.16 8 11933 207 110577151
Corneal oedema 38.29 19.16 14 11927 3159 110574199
Sleep apnoea syndrome 38.14 19.16 33 11908 40414 110536944
Loss of personal independence in daily activities 37.50 19.16 62 11879 149958 110427400
Tinnitus 37.24 19.16 39 11902 60501 110516857
Lung disorder 34.20 19.16 66 11875 179981 110397377
Urticaria 33.99 19.16 93 11848 318764 110258594
Cystoid macular oedema 32.48 19.16 12 11929 2788 110574570
Cystitis 31.09 19.16 37 11904 65999 110511359
Retinal oedema 30.60 19.16 10 11931 1617 110575741
Drug intolerance 29.76 19.16 104 11837 406408 110170950
Pulmonary embolism 29.58 19.16 69 11872 214405 110362953
Clostridium difficile infection 29.27 19.16 32 11909 52097 110525261
Breath odour 28.61 19.16 10 11931 1982 110575376
Spinal muscular atrophy 28.21 19.16 7 11934 420 110576938
Maculopathy 28.01 19.16 11 11930 3016 110574342
Rash 24.55 19.16 162 11779 820802 109756556
Cross sensitivity reaction 24.53 19.16 12 11929 5555 110571803
Bronchitis 24.41 19.16 53 11888 156979 110420379
Skin exfoliation 24.32 19.16 38 11903 87613 110489745
Ocular toxicity 24.26 19.16 8 11933 1330 110576028
Inhibitory drug interaction 22.81 19.16 11 11930 4936 110572422
Pruritus 22.64 19.16 123 11818 581437 109995921
Toxic epidermal necrolysis 22.24 19.16 29 11912 56698 110520660
Agitation 22.14 19.16 42 11899 113009 110464349
Drug reaction with eosinophilia and systemic symptoms 21.96 19.16 35 11906 82060 110495298
Clostridium test positive 21.86 19.16 14 11927 10879 110566479
Rash maculo-papular 21.75 19.16 33 11908 74189 110503169
Hallucination 21.52 19.16 39 11902 101393 110475965
Oral discomfort 21.38 19.16 14 11927 11297 110566061
White blood cells urine positive 21.13 19.16 12 11929 7512 110569846
Oesophagitis haemorrhagic 20.63 19.16 6 11935 659 110576699
Motor neurone disease 20.12 19.16 6 11935 718 110576640
Peritonitis 20.04 19.16 21 11920 32586 110544772
Fluid retention 19.67 19.16 36 11905 94271 110483087
Product impurity 19.67 19.16 4 11937 96 110577262
Intestinal perforation 19.56 19.16 17 11924 20927 110556431
Joint swelling 19.28 19.16 12 11929 442833 110134525

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:88188 drug allergen
CHEBI has role CHEBI:35441 antiinfective agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Gonorrhea indication 15628003 DOID:7551
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Lyme disease indication 23502006 DOID:11729
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Gonorrhea of rectum indication 42746002
Impetigo indication 48277006 DOID:8504
Lower respiratory tract infection indication 50417007
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute maxillary sinusitis indication 68272006 DOID:2050
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Escherichia coli urinary tract infection indication 301011002
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Streptococcus Pneumoniae Chronic Bronchitis indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Haemophilus Influenzae Chronic Bronchitis indication
Streptococcus Pneumoniae Bronchitis indication
Haemophilus Influenzae Bronchitis indication
Haemophilus Parainfluenzae Bronchitis indication
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.75 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4017552 VUID
N0000179073 NUI
D00914 KEGG_DRUG
20493 RXNORM
C0055015 UMLSCUI
CHEBI:3516 CHEBI
KOV PDB_CHEM_ID
CHEMBL1095930 ChEMBL_ID
C040738 MESH_SUPPLEMENTAL_RECORD_UI
Z49QDT0J8Z UNII
6321416 PUBCHEM_CID
1053 MMSL
4388 MMSL
46962 MMSL
d00056 MMSL
002730 NDDF
003590 NDDF
372833007 SNOMEDCT_US
73986003 SNOMEDCT_US
89678001 SNOMEDCT_US
C0007562 UMLSCUI
DB01112 DRUGBANK_ID
5479529 PUBCHEM_CID
3902 INN_ID
4017552 VANDF
4019668 VANDF
D002444 MESH_DESCRIPTOR_UI
CHEBI:3515 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefuroxime axetil Human Prescription Drug Label 1 0904-7542 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Cefuroxime axetil Human Prescription Drug Label 1 0904-7542 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
CEFUROXIME AXETIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-215 TABLET, FILM COATED 500 mg ORAL ANDA 21 sections
Cefuroxime Axetil Human Prescription Drug Label 1 16714-400 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 16714-401 TABLET 500 mg ORAL ANDA 24 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 21695-150 TABLET 500 mg ORAL ANDA 25 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 21695-370 TABLET 250 mg ORAL ANDA 25 sections
Cefuroxime Axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-623 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-623 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-656 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-656 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-657 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 43063-657 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-0781 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-0781 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-0782 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime axetil Human Prescription Drug Label 1 50090-2157 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Cefuroxime axetil Human Prescription Drug Label 1 50090-2158 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime axetil Human Prescription Drug Label 1 50090-2159 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-4153 TABLET 500 mg ORAL ANDA 26 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-4153 TABLET 500 mg ORAL ANDA 26 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-6999 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-7095 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-7667 TABLET 250 mg ORAL ANDA 24 sections
Cefuroxime Axetil Human Prescription Drug Label 1 50090-7668 TABLET 500 mg ORAL ANDA 24 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 51407-333 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Cefuroxime axetil HUMAN PRESCRIPTION DRUG LABEL 1 51407-334 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Cefuroxime axetil Human Prescription Drug Label 1 52959-308 TABLET, FILM COATED 250 mg ORAL ANDA 14 sections
Cefuroxime Axetil Human Prescription Drug Label 1 52959-939 TABLET 500 mg ORAL ANDA 27 sections
Cefuroxime axetil Human Prescription Drug Label 1 53002-2670 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections